Transluminal catheter dilatation. Indications, technical aspects, results

Prior research has shown that percutaneous transluminal angioplasty (PTA) has variable success rates depending on lesion characteristics and patient symptoms. It was already known that PTA is commonly used to treat peripheral arterial disease, but the long-term patency rates remained uncertain. No prior work had resolved the impact of lesion length and patient symptoms on outcomes. This gap motivated a study to assess follow-up patency rates over 18 years. Claudication and rest pain are distinct clinical presentations with unclear differences in PTA success. The role of lesion length in determining outcomes had not been fully established. Technical aspects of PTA varied widely, with no consensus on optimal indications. This uncertainty drove the need for a structured, prospective analysis of PTA results.

The aim of this study was to evaluate the long-term patency rates of PTA in patients with peripheral arterial disease. The specific problem addressed was the variability in outcomes based on lesion length and patient symptoms. The motivation stemmed from the need to guide clinical decisions regarding PTA indications. The study focused on comparing outcomes in patients with claudication versus rest pain or gangrene. Lesion length was identified as a key factor influencing success rates. The goal was to determine if shorter occlusions in the superficial femoral artery correlated with better results. The study also aimed to clarify the role of PTA in limb salvage. These findings could help refine patient selection for PTA procedures.

The study used a prospective design to track patency rates after PTA over 18 years. Patients were grouped based on symptoms: claudication, rest pain, or gangrene. Lesion length in the superficial femoral artery was measured as a key variable. Follow-up periods extended up to five years to assess long-term patency. Technical details of PTA procedures were recorded, including success rates and complications. Patients with occlusions under 12 cm were compared to those with longer occlusions. The primary outcome was the patency rate at five years. Secondary outcomes included limb salvage rates and primary success rates.

The five-year patency rate was 85 to 89% in patients with claudication and shorter occlusions. For patients with rest pain or gangrene, the rate was 65 to 72%. Lesions longer than 12 cm had lower success rates. The primary success rate for claudication patients with longer occlusions was 68%. Follow-up patency remained high despite lower initial success. Patients with gangrene and long occlusions had only 52% primary success. Their five-year patency rate dropped to 30%. PTA saved limbs in 42% of this high-risk group.

The authors suggest that PTA outcomes depend on lesion length and patient symptoms. Claudication patients with shorter occlusions had the best five-year patency rates. Rest pain and gangrene patients showed lower success rates. Lesions over 12 cm correlated with poorer outcomes. The authors propose that PTA may still be beneficial in some high-risk cases. Limb salvage was achieved in 42% of gangrene patients with long occlusions. Technical details and indications were discussed in the context of these findings. These results may help guide treatment decisions for PTA.